Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Terminated 2Active not recruiting 2Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other 2

Conditions

Breast Neoplasms 989Neoplasms 848Carcinoma, Non-Small-Cell Lung 842Prostatic Neoplasms 527Neoplasm Metastasis 500Leukemia, Myeloid, Acute 488Melanoma 453Colorectal Neoplasms 446Multiple Myeloma 440Lung Neoplasms 419Pancreatic Neoplasms 352Recurrence 350Lymphoma 349Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 327Leukemia 323Leukemia, Lymphocytic, Chronic, B-Cell 301Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 243Carcinoma, Hepatocellular 234Squamous Cell Carcinoma of Head and Neck 231Glioblastoma 231Myelodysplastic Syndromes 229Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

ART123 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × Chemotherapy-induced Peripheral Neuropathy × Clear all
NCT05371158 2025-08-15

QLIPP-CIPN

Tilburg University

Phase NA Terminated
112 enrolled
Other

Chemotherapy-induced Peripheral Neuropathy

NCT05251727 2024-08-19

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Veloxis Pharmaceuticals

Phase 1 Terminated
77 enrolled
Other

Chemotherapy-induced Peripheral Neuropathy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡